Thinking beyond intravenous immunoglobulin for Kawasaki disease

Anne Sage,Ankur Kumar Jindal,Athimalaipet V Ramanan
DOI: https://doi.org/10.1136/archdischild-2023-325843
2023-09-20
Pediatria Polska
Abstract:Kawasaki disease (KD), a medium vessel vasculitis of unknown aetiology, remains the leading cause of acquired heart disease in children of developed nations and is being increasingly recognised in low-income and middle-income countries. Although introduction of intravenous immunoglobulin (IVIG) has been unequivocally proven to significantly reduce the risk of KD-associated coronary artery aneurysms (CAAs), the literature suggests that as high as 19% of children will still develop cardiac sequelae even with timely administration.1 Established risk factors for development of CAAs include coronary artery dilatation at baseline echocardiogram, young age (<12 months), male sex, persistence or recrudescence of fever 36 hours post IVIG administration and Asian race.2 Given the acute and long-term morbidity that can be associated with coronary artery involvement, several adjunctive agents to IVIG have been studied for primary intensification or subsequent treatment. Despite extensive research, heterogeneity of study subjects, drug dosing, outcome measures...
What problem does this paper attempt to address?